[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Ueno H, Ikeda M: [Two cases of advanced extrahepatic bile duct cancer successfully treated by S-1 monotherapy]. Gan To Kagaku Ryoho; 2007 Aug;34(8):1311-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of advanced extrahepatic bile duct cancer successfully treated by S-1 monotherapy].
  • Biliary tract cancers, including extrahepatic bile duct cancer, are often diagnosed at an advanced stage; however,no standard therapies have been established as yet for this disease,and new,effective chemotherapeutic agents are being sought.
  • Recently, a late phase II study of S-1, an oral fluoropyrimidine, in 40 patients with advanced biliary tract cancer yielded a good response rate of 35.0%.
  • In this article,we report two patients with advanced extrahepatic bile duct cancer enrolled in the study who showed a partial response to S-1 monotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Bile Duct Neoplasms / drug therapy. Bile Ducts, Extrahepatic. Oxonic Acid / administration & dosage. Tegafur / administration & dosage
  • [MeSH-minor] Drug Administration Schedule. Drug Combinations. Female. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Quality of Life

  • Genetic Alliance. consumer health - Extrahepatic bile duct cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687221.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


2. Abou-Alfa GK, Rowinsky EK, Patt YZ, Schwartz GK, Kelsen DP, Sharma S, Siegel E, Becerra CR, Eckhardt SG, Feit K, De Jager R, O'Reilly EM: A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. Am J Clin Oncol; 2005 Aug;28(4):334-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.
  • A multicenter phase II study to determine the antitumor activity of exatecan was conducted in patients with advanced cholangiocarcinoma and gallbladder carcinoma.
  • Exatecan was administered at a dose of 0.5 mg/m2 IV over 30 minutes daily on days 1 through 5 every 21 days.
  • The primary end point was overall response rate: complete response and partial response (PR).
  • A Simon optimal 2-stage design was employed.
  • Two of 41 evaluated patients (4.9%) had a PR, 4 patients (9.8%) had a minor response, and 12 had stable disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Camptothecin / analogs & derivatives. Cholangiocarcinoma / drug therapy. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Drug Administration Schedule. Female. Half-Life. Humans. Male. Middle Aged. Survival Rate. Topoisomerase I Inhibitors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16062073.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Topoisomerase I Inhibitors; 0 / exatecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


3. Mizushima T, Sugiura T, Hori S, Ito T, Mizuno H, Hoki M, Souma Y, Kainuma S, Yamanaka H, Ozawa H, Kanou T, Nakamori Y, Iwase K: [A case of postoperative liver metastasis from bile duct carcinoma responding to transarterial chemoembolization]. Gan To Kagaku Ryoho; 2006 Feb;33(2):263-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of postoperative liver metastasis from bile duct carcinoma responding to transarterial chemoembolization].
  • A 77-year-old man underwent pylorus-preserving pancreatoduodenectomy for bile duct carcinoma in October 2000.
  • Histological diagnosis was moderately-differentiated tubular adenocarcinoma, pT 2 (ss, pHinf 0, pPanc 1, pPV 0, pA 0), pN 0, and final Stage II.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bile Duct Neoplasms / surgery. Chemoembolization, Therapeutic. Liver Neoplasms / secondary. Liver Neoplasms / therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Epirubicin / administration & dosage. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Male. Microspheres. Mitomycin / administration & dosage. Polymers. Postoperative Period. Remission Induction

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484870.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Polymers; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Tanida T, Tanemura M, Kobayashi S, Wada H, Marubashi S, Eguchi H, Takeda Y, Umeshita H, Mori M, Doki Y, Nagano H: [A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2729-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathological stage was T2N0M0, Stage II with moderately differentiated intrahepatic cholangiocarcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Drug Combinations. Female. Hepatic Artery. Humans. Infusions, Intra-Arterial. Neoplasm Recurrence, Local. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224694.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Cai HH, Sun YM, Bai JF, Shi Y, Zhao HL, Miao Y: Relationship between the GH-IGFs axis and the proliferation of bile duct cancer cell line QBC939 in vitro. Hepatobiliary Pancreat Dis Int; 2008 Feb;7(1):76-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between the GH-IGFs axis and the proliferation of bile duct cancer cell line QBC939 in vitro.
  • In the current study, we assessed the proliferation of a bile duct cancer cell line (QBC939) in vitro with GH and explored the possible relationship with the axis of GH-IGFs (insulin-like growth factors).
  • METHODS: QBC939 cells in the exponential growth stage were harvested and divided into an experimental group (GH group) and a control group (NS group).
  • The GH group was divided into four sub-groups according to the dose of GH and culture time (50 microg/L for 2 hours, 50 microg/L for 24 hours, 100 microg/L for 2 hours, 100 microg/L for 24 hours).
  • The NS group was divided into two sub-groups (NS for 2 hours and NS for 24 hours).
  • After 2 or 24 hours, IGF-1 and IGF-2 were detected using the enzyme-linked immunosorbent assay.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / pathology. Human Growth Hormone / pharmacology. Insulin-Like Growth Factor I / genetics. Insulin-Like Growth Factor II / genetics
  • [MeSH-minor] Cell Division / drug effects. Cell Division / physiology. Cell Line, Tumor. Cytoplasm / physiology. Humans. In Vitro Techniques. Mitogens / pharmacology. RNA, Messenger / metabolism. S Phase / drug effects. S Phase / physiology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18234643.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mitogens; 0 / RNA, Messenger; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down






Advertisement